These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 22520143)
1. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Zaman K; Yunus M; El Arifeen S; Azim T; Faruque AS; Huq E; Hossain I; Luby SP; Victor JC; Dallas MJ; Lewis KD; Rivers SB; Steele AD; Neuzil KM; Ciarlet M; Sack DA Vaccine; 2012 Apr; 30 Suppl 1():A94-100. PubMed ID: 22520143 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140 [TBL] [Abstract][Full Text] [Related]
3. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Feller AJ; Zaman K; Lewis KD; Hossain I; Yunus M; Sack DA Vaccine; 2012 Apr; 30 Suppl 1():A101-5. PubMed ID: 22520118 [TBL] [Abstract][Full Text] [Related]
4. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants. Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138 [TBL] [Abstract][Full Text] [Related]
5. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132 [TBL] [Abstract][Full Text] [Related]
6. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Shin S; Anh DD; Zaman K; Yunus M; Mai le TP; Thiem VD; Azim T; Victor JC; Dallas MJ; Steele AD; Neuzil KM; Ciarlet M Vaccine; 2012 Apr; 30 Suppl 1():A106-13. PubMed ID: 22520119 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Feikin DR; Laserson KF; Ojwando J; Nyambane G; Ssempijja V; Audi A; Nyakundi D; Oyieko J; Dallas MJ; Ciarlet M; Neuzil KM; Breiman RF Vaccine; 2012 Apr; 30 Suppl 1():A52-60. PubMed ID: 22520137 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Zaman K; Dang DA; Victor JC; Shin S; Yunus M; Dallas MJ; Podder G; Vu DT; Le TP; Luby SP; Le HT; Coia ML; Lewis K; Rivers SB; Sack DA; Schödel F; Steele AD; Neuzil KM; Ciarlet M Lancet; 2010 Aug; 376(9741):615-23. PubMed ID: 20692031 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Armah GE; Sow SO; Breiman RF; Dallas MJ; Tapia MD; Feikin DR; Binka FN; Steele AD; Laserson KF; Ansah NA; Levine MM; Lewis K; Coia ML; Attah-Poku M; Ojwando J; Rivers SB; Victor JC; Nyambane G; Hodgson A; Schödel F; Ciarlet M; Neuzil KM Lancet; 2010 Aug; 376(9741):606-14. PubMed ID: 20692030 [TBL] [Abstract][Full Text] [Related]
11. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH; Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Madhi SA; Kirsten M; Louw C; Bos P; Aspinall S; Bouckenooghe A; Neuzil KM; Steele AD Vaccine; 2012 Apr; 30 Suppl 1():A44-51. PubMed ID: 22520136 [TBL] [Abstract][Full Text] [Related]
13. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL; Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Armah GE; Breiman RF; Tapia MD; Dallas MJ; Neuzil KM; Binka FN; Sow SO; Ojwando J; Ciarlet M; Steele AD Vaccine; 2012 Apr; 30 Suppl 1():A86-93. PubMed ID: 22520142 [TBL] [Abstract][Full Text] [Related]
16. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534 [TBL] [Abstract][Full Text] [Related]
17. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies. Li RC; Li YP; Mo ZJ; Luo D; Huang T; Kong JL; Wang LH; Song NS; Liu A; Zhang H; Liao X; Karkada N; Han HH Hum Vaccin Immunother; 2013 Aug; 9(8):1638-42. PubMed ID: 23807360 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM; Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266 [TBL] [Abstract][Full Text] [Related]
19. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Tregnaghi MW; Abate HJ; Valencia A; Lopez P; Da Silveira TR; Rivera L; Rivera Medina DM; Saez-Llorens X; Gonzalez Ayala SE; De León T; Van Doorn LJ; Pilar Rubio MD; Suryakiran PV; Casellas JM; Ortega-Barria E; Smolenov IV; Han HH; Pediatr Infect Dis J; 2011 Jun; 30(6):e103-8. PubMed ID: 21378594 [TBL] [Abstract][Full Text] [Related]
20. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]